Zentalis Pharmaceuticals Llc Stock In The News
| ZNTL Stock | USD 3.23 0.05 1.57% |
Our overall analysis of Zentalis Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Zentalis Pharmaceuticals Llc. The specific impact of Zentalis Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Zentalis Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Zentalis Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Zentalis Pharmaceuticals Backtesting and Zentalis Pharmaceuticals Hype Analysis.
Zentalis |
Zentalis Pharmaceuticals Today Top News and Investor Outlook
Zentalis Pharmaceuticals Llc Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Zentalis and other traded companies coverage with news coverage. We help investors stay connected with Zentalis headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Zentalis Stock performance. Please note that trading solely based on the Zentalis Pharmaceuticals Llc hype is not for everyone as timely availability and quick action are needed to avoid losses.
Zentalis Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Zentalis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Zentalis Pharmaceuticals that are available to investors today. That information is available publicly through Zentalis media outlets and privately through word of mouth or via Zentalis internal channels. However, regardless of the origin, that massive amount of Zentalis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zentalis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zentalis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zentalis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zentalis Pharmaceuticals alpha.
Zentalis Largest EPS Surprises
Earnings surprises can significantly impact Zentalis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-09 | 2020-09-30 | -0.81 | -0.91 | -0.1 | 12 | ||
2023-11-06 | 2023-09-30 | -0.91 | -0.79 | 0.12 | 13 | ||
2023-03-01 | 2022-12-31 | -1.06 | -0.92 | 0.14 | 13 | ||
2022-08-09 | 2022-06-30 | -1.19 | -1.34 | -0.15 | 12 | ||
2021-08-12 | 2021-06-30 | -1.17 | -1.34 | -0.17 | 14 | ||
2022-11-09 | 2022-09-30 | -1.17 | -0.96 | 0.21 | 17 |
Zentalis Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Zentalis Pharmaceuticals Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm at gurufocus.com
13th of November 2024
Zentalis Pharmaceuticals names Julie Eastland as CEO at seekingalpha.com
1st of November 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 at finance.yahoo.com
18th of October 2024
State Street Corps Strategic Reduction in Zentalis Pharmaceuticals Holdings at gurufocus.com
7th of October 2024
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc at gurufocus.com
26th of September 2024
Decheng Capital LLC Has 12.56 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. - M... at news.google.com
17th of September 2024
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies at zacks.com
16th of September 2024
FDA Removes Partial Hold On Zentalis Pharmaceuticals Azenosertib Studies In Patients With ... at finance.yahoo.com
9th of September 2024
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zentalis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zentalis Pharmaceuticals' short interest history, or implied volatility extrapolated from Zentalis Pharmaceuticals options trading.
Check out Zentalis Pharmaceuticals Backtesting and Zentalis Pharmaceuticals Hype Analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.